NCT01230736CompletedPhase 4
Assessing the Safety and Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients Uncontrolled on Bimatoprost 0.03%/Timolol 0.5% Therapy (Fixed or Unfixed)
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Alcon Research
- Enrollment
- 105
- Primary Endpoint
- Change in Intraocular Pressure (IOP) at 8 weeks from prior therapy (baseline)
Study Overview
Brief Summary
The purpose of this study to assess the safety and efficacy of changing to DuoTrav® from prior bimatoprost 0.03%/timolol 0.5% (used concomitantly or in a fixed combination) pharmacotherapy in uncontrolled patients with open-angle glaucoma or ocular hypertension.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Must have a clinical diagnosis of ocular hypertension, primary open-angle or pigment dispersion glaucoma in both eyes.
- •Must have an IOP of between 19 to 35 millimeters mercury (mmHg) (at any time of the day) in at least one eye (which would be designated as the study eye).
- •Must be willing to discontinue the use of all other ocular hypotensive medication(s) prior to receiving the study medication for the entire course of the study.
- •Women who are pregnant or lactating.
- •Other protocol-defined inclusion criteria may apply.
Exclusion Criteria
- •Known medical history of allergy, hypersensitivity or poor tolerance to any component of DuoTrav® that is deemed clinically significant in the opinion of the Principal Investigator.
- •Corneal dystrophies in either eye.
- •Risk of visual field or visual acuity worsening as a consequence of participation in the study, in the investigator's best judgment.
- •Bronchial asthma or a history of bronchial asthma, bronchial hyper-reactivity, or severe chronic obstructive pulmonary disease that would preclude the safe administration of a topical beta-blocker.
- •History of severe allergic rhinitis.
- •Other protocol-defined exclusion criteria may apply.
Arms & Interventions
DuoTrav
Experimental
One drop in study eye(s) once daily for 8 weeks
Intervention: Travoprost 0.004%/Timolol 0.5% Fixed Combination eye drops solution (Duotrav®) (Drug)
Outcomes
Primary Outcomes
Change in Intraocular Pressure (IOP) at 8 weeks from prior therapy (baseline)
Time Frame: 8 weeks
Goldmann applanation tonometry will be performed at the baseline visit and 8-week visit to record intraocular pressure (IOP). The difference between the two readings will be recorded as the change in IOP. IOP will be recorded in mmHg.
Secondary Outcomes
- Percentage of subjects who reach target IOP (≤18 mmHg)(8 weeks)
Investigators
Similar Trials
Completed
Phase 4
Efficacy of Changing to DUOTRAV® From Prior TherapyPigment Dispersion GlaucomaOpen-Angle GlaucomaOcular HypertensionNCT01327599Alcon Research60
Terminated
Phase 4
Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination) From Prior TherapyGlaucomaNCT01514721Alcon Research37
Withdrawn
Phase 4
Assessing the Efficacy of DuoTrav as a Replacement Therapy in Glaucoma Patients in RussiaGlaucomaOcular HypertensionNCT01696383Alcon Research
Completed
Not Applicable
Dolutegravir-based Dual Therapies in HIV-infected Patients With Virological SuppressionHIV InfectionNCT02491242Asociacion para el Estudio de las Enfermedades Infecciosas155
Active, not recruiting
Phase 3
B/F/TAF to DTG/3TC Switch StudyHIV-1-infectionNCT06444620University of Nairobi240